Safety and feasibility of thoracoscopic pericardial window in recurrent pericardial effusion - A single-centre experience.

Mohan Venkatesh Pulle, Manish Bansal, Belal Bin Asaf, Harsh Vardhan Puri, Sukhram Bishnoi, Arvind Kumar
{"title":"Safety and feasibility of thoracoscopic pericardial window in recurrent pericardial effusion - A single-centre experience.","authors":"Mohan Venkatesh Pulle, Manish Bansal, Belal Bin Asaf, Harsh Vardhan Puri, Sukhram Bishnoi, Arvind Kumar","doi":"10.4103/jmas.jmas_144_22","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study aimed to report the surgical outcomes and also evaluating the safety and feasibility of thoracoscopic pericardial window (PW) for recurrent pericardial effusion.</p><p><strong>Materials and methods: </strong>This was a retrospective analysis of eight cases of recurrent pericardial effusion, managed by thoracoscopic method in a tertiary-level thoracic surgery centre over 5 years. A detailed analysis of all perioperative variables, including complications, was carried out.</p><p><strong>Results: </strong>A total of eight patients underwent thoracoscopic PW during the study period. Males (87.5%) were predominant in the cohort. The median age was 54 years (range: 28-78 years). The median duration of symptoms was 2 months (range: 1-3 months). Tuberculosis (50%), malignancy (37.5%) and chronic kidney disease (12.5%) were the causes of recurrent effusion. All patients underwent thoracoscopic procedure with no conversions. The median operative time was 45 min (range: 40-70 min). The median effusion volume drained was 500 ± 100 ml. The median hospital stay was 3 days (range: 2-4 days) with no post-procedural complications. All the patients had complete resolution of symptoms. No recurrence was noted in the median follow-up period of 28 months (range: 6-60 months).</p><p><strong>Conclusions: </strong>Thoracoscopic PW is a safe and feasible minimally invasive option in the management of recurrent pericardial effusion in selected patients. Surgical fitness, haemodynamic status and estimated survival (in malignant effusion) should be considered before the procedure.</p>","PeriodicalId":50243,"journal":{"name":"Journal of Cellular and Comparative Physiology","volume":"5 1","pages":"19-23"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10898635/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cellular and Comparative Physiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/jmas.jmas_144_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/10/31 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: This study aimed to report the surgical outcomes and also evaluating the safety and feasibility of thoracoscopic pericardial window (PW) for recurrent pericardial effusion.

Materials and methods: This was a retrospective analysis of eight cases of recurrent pericardial effusion, managed by thoracoscopic method in a tertiary-level thoracic surgery centre over 5 years. A detailed analysis of all perioperative variables, including complications, was carried out.

Results: A total of eight patients underwent thoracoscopic PW during the study period. Males (87.5%) were predominant in the cohort. The median age was 54 years (range: 28-78 years). The median duration of symptoms was 2 months (range: 1-3 months). Tuberculosis (50%), malignancy (37.5%) and chronic kidney disease (12.5%) were the causes of recurrent effusion. All patients underwent thoracoscopic procedure with no conversions. The median operative time was 45 min (range: 40-70 min). The median effusion volume drained was 500 ± 100 ml. The median hospital stay was 3 days (range: 2-4 days) with no post-procedural complications. All the patients had complete resolution of symptoms. No recurrence was noted in the median follow-up period of 28 months (range: 6-60 months).

Conclusions: Thoracoscopic PW is a safe and feasible minimally invasive option in the management of recurrent pericardial effusion in selected patients. Surgical fitness, haemodynamic status and estimated survival (in malignant effusion) should be considered before the procedure.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
胸腔镜心包开窗治疗复发性心包积液的安全性和可行性 - 单中心经验。
背景:本研究旨在报告手术结果,并评估胸腔镜心包开窗术(PW)治疗复发性心包积液的安全性和可行性:本研究旨在报告胸腔镜心包开窗术(PW)治疗复发性心包积液的手术效果,并评估其安全性和可行性:这是一项回顾性分析,研究对象是一家三级胸外科中心5年来用胸腔镜方法治疗的8例复发性心包积液患者。对包括并发症在内的所有围手术期变量进行了详细分析:研究期间共有8名患者接受了胸腔镜PW手术。男性占多数(87.5%)。中位年龄为 54 岁(28-78 岁)。症状持续时间的中位数为 2 个月(范围:1-3 个月)。肺结核(50%)、恶性肿瘤(37.5%)和慢性肾病(12.5%)是导致反复流脓的原因。所有患者均接受了胸腔镜手术,无一例转院。手术时间中位数为 45 分钟(40-70 分钟不等)。排出的中位积液量为 500 ± 100 毫升。中位住院时间为 3 天(2-4 天不等),无术后并发症。所有患者的症状均已完全缓解。中位随访期为 28 个月(6-60 个月),无复发:结论:胸腔镜 PW 是治疗复发性心包积液的一种安全可行的微创方法。手术前应考虑手术适应性、血液动力学状态和估计存活率(恶性积液)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Safety and feasibility of thoracoscopic pericardial window in recurrent pericardial effusion - A single-centre experience. Management of NF2-associated vestibular schwannomas in children and young adults: influence of surgery and clinical factors on tumor volume and growth rate. The influence of rat and frog liver enzymes on the hydrolysis of ortho and pyrophosphoric esters of thiamine The attachment of glycolytic enzymes to muscle ultrastructure REACTION OF SOME MUTAGENIC AND CARCINOGENIC COMPOUNDS WITH NUCLEIC ACIDS.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1